ArticleNeuropsychiatric disease and treatment2021
Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J.
Article in Neuropsychiatric disease and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Change in Cognitive Function over the Course of Major Depressive Disorder: A Systematic Review and Meta-analysis.Neuropsychology review · 2025Pooled it
- Predictors of Improvement in Subjective Executive Functioning Following an Internet-Delivered Cognitive Enhancement Intervention for Adults in Remission From Depression.Acta psychiatrica Scandinavica · 2026Trial
- Effectiveness of cognitive remediation in subjects with major depressive disorder: A multicenter randomized controlled study in a real-world setting.European psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- The Effects of Adding Art Therapy to Ongoing Antidepressant Treatment in Moderate-to-Severe Major Depressive Disorder: A Randomized Controlled Study.International journal of environmental research and public health · 2022Trial
- Development of a baseline battery to optimize depression treatment assignment in primary care: Balancing breadth and brevity.Journal of affective disorders · 2026Article
- A Secondary Analysis of Longitudinal Pilot-Study Data Investigating the Associations Between Health-Related Quality of Life and Executive Functions in Remitted Major Depressive Disorder and Developments Two-Years Following Cognitive Training.Scandinavian journal of psychology · 2026Article
- Virtual reality-based cognitive remediation in severe mental illness: Current evidence from a narrative review.Schizophrenia research. Cognition · 2026Review
- Cognitive function and depressive symptoms in major depressive disorder: a smartphone-based study of outpatients from a sleep-disorders clinic in China.Frontiers in psychiatry · 2026Article
- Exploring risky decision-making dynamics during antidepressant treatment in major depressive disorder: a computational modeling approach.BMC psychiatry · 2025Article
- A longitudinal analysis of the relationship between emotional symptoms and cognitive function in patients with major depressive disorder.Psychological medicine · 2025Article
- Cognitive Deficits in Late-Life Depression: From Symptoms and Assessment to Therapeutics.Focus (American Psychiatric Publishing) · 2025Review
- Longitudinal trajectories of subjective cognitive complaints in patients with major depressive disorder and similar objective cognitive trajectories.BMC psychiatry · 2025Observational
- Association of Blood Cell-Derived Inflammatory Markers with Symptoms and Short-Term Treatment Response in Late-Life Depression.Neuropsychiatric disease and treatment · 2025Article
- Improvement in self-reported cognitive functioning but not in rumination following online working memory training in a two-year follow-up study of remitted major depressive disorder.Frontiers in psychiatry · 2023Article
- Psychological-health correlates of physical activity and sedentary behaviour during the COVID pandemic.Mental health and physical activity · 2022Article
- Real-World Functioning in Psychiatric Outpatients: Predictive Factors.Journal of clinical medicine · 2022Article
- Occupational Therapy in Severe Mental Disorder-A Self-Controlled Quasi-Experimental Study.Healthcare (Basel, Switzerland) · 2022Article
- Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study.Neuropsychopharmacology reports · 2022Article
- Subjective cognitive complaints and cardiovascular risk factors in older Mexican Americans: A cross-sectional study.Cerebral circulation - cognition and behavior · 2022Article
- Validation and Functional Relevance of the Short Form of the Perceived Deficits Questionnaire for Depression for Japanese Patients with Major Depressive Disorder.Neuropsychiatric disease and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulating evidence suggests the presence of cognitive impairment in patients with major depressive disorder (MDD), which affects their psychosocial function and quality of life (QoL). PERFORM-J (Prospective Epidemiological Research on Functioning Outcomes Related to MDD in Japan) is an observational, multicenter study to assess longitudinal changes in depressive symptoms, psychomotor speed, subjective cognitive function, and psychosocial function.
methodsFive hundred and eighteen Japanese outpatients with MDD initiating new antidepressant monotherapy (first-line or switch from previous drug) as part of their routine medical care participated in this study. Assessments at baseline and over the 6-month observation period included physician-rated depression severity (Montgomery-Åsberg Depression Rating Scale), psychomotor speed (Digit Symbol Substitution Test; DSST), subjective cognition (Perceived Deficits Questionnaire-Depression), psychosocial function (Sheehan Disability Scale), and QoL (EuroQol-5 Dimension-5 Level).
resultsAntidepressant treatment for 6 months improved depressive symptoms and subjective cognitive impairment (cognitive complaints), whereas psychomotor speed remained impaired (ie, DSST total score was >1 standard deviation below the norm) in 35.6% of patients at 6 months. Impairment of subjective cognition, but not psychomotor speed at month 2 was associated with poor psychosocial function and QoL at 6 months. There was a trend for higher relapse rates at 6 months in patients with greater subjective cognitive impairment at 2 months.
conclusionThese findings highlight the importance of evaluating cognitive difficulties to predict long-term outcomes in patients with MDD. Early intervention for cognitive complaints may decrease the relapse rate, which warrants further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.